Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrated Stress Response (ISR) Modulator Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PPP1R15B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PPP1R15B Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI and enzymatic assays. |
View PPP1R15B Products |
| Gene Delivery | PPP1R15B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and ISR pathway reporter assays. |
View PPP1R15B Products |
| Benchmark Ab | Anti-PPP1R15B Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and IP validation. |
View PPP1R15B Products |
| Validator | PPP1R15B siRNA Set For target knockdown verification and target validation studies. |
View PPP1R15B Products |
| Related Target A | PPP1R15A (GADD34) Closely related isoform; essential counter-screening target to ensure drug selectivity. |
View PPP1R15A Products |
| Related Target B | EIF2S1 (eIF2α) Direct downstream substrate of the PPP1R15B-PP1 phosphatase complex. |
View EIF2S1 Products |
| Related Target C | PPP1CA (PP1 catalytic subunit alpha) Binding partner that forms the active holophosphatase complex with PPP1R15B. |
View PPP1CA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity screening against PPP1R15A (GADD34) | Highly purified recombinant PPP1R15B and PPP1R15A proteins available for comparative binding assays. |
| Reconstitution of active holophosphatase complex | Co-purification grade PPP1R15B and PPP1CA catalytic subunits with verified sequence and high purity (>95%). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control antibodies included. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification in cell-based assays. |
Live PPP1R15B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Integrated Stress Response (ISR) pathway is rapidly expanding, with PPP1R15B (CreP) emerging as a high-value target. Unlike its stress-induced counterpart PPP1R15A (GADD34), PPP1R15B is constitutively expressed and maintains basal eIF2α dephosphorylation. The race for PPP1R15B therapeutics is intensifying, with major players shifting focus from non-selective phosphatase inhibitors to highly selective small molecule protein-protein interaction (PPI) disruptors and PROTACs. As first-generation therapies reach preclinical milestones, the next wave of R&D is targeting tissue-specific delivery and combination regimens with proteasome inhibitors to trigger selective apoptosis in secretory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Calico Life Sciences, AbbVie, InMed | Neurodegenerative Diseases (ALS, Alzheimer's, Charcot-Marie-Tooth) | Disruption Assay (Need high-purity PPP1R15B and PPP1CA for TR-FRET/AlphaLISA) |
| PROTAC / Degrader | Arvinas, Academic Spin-offs | Multiple Myeloma, Secretory Cancers | Ubiquitination Assay (Need sequence-verified PPP1R15B recombinant protein) |
| Gene Therapy / RNAi | Alnylam, Ionis | Metabolic Disorders, Rare Neuropathies | Knockdown Validation (Need validated PPP1R15B siRNA and Lentivirus) |